Drugs / Universal Donor (UD) TGFβi NK Cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06450041 | Dec 2024 → Dec 2028 expected | neuroblastoma | New Approaches to Neuroblastoma Therapy Consortium | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Universal Donor (UD) TGFβi NK Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06450041 ↗ |
| Modality | Cell therapy | “Ex-Vivo Expanded Allogeneic Universal Donor TGFβi NK Cell Infusions” NCT06450041 ↗ |